Welcome to our dedicated page for Nanobiotix S.A. SEC filings (Ticker: NBTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nanobiotix S.A. (NBTX) SEC filings page brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on the Nasdaq Global Select Market. Nanobiotix files reports such as Form 6-K current reports, which often include press releases on clinical, financial, and corporate developments.
Through these filings, investors can access official information on topics such as the JNJ-1900 (NBTXR3) clinical development program, including updates on the global Phase 3 NANORAY-312 study in head and neck squamous cell cancers and other studies sponsored by Nanobiotix or The University of Texas MD Anderson Cancer Center. Filings may also incorporate details on the company’s collaboration and license agreement with Janssen Pharmaceutica NV for global co-development and commercialization of JNJ-1900 (NBTXR3).
SEC submissions can further describe Nanobiotix’s financing arrangements, including royalty-based agreements with HealthCare Royalty (HCRx) that relate to milestones and royalties on JNJ-1900 (NBTXR3). Investors can review these documents to understand how such transactions interact with expected future payments under the Janssen license agreement.
Because Nanobiotix is also listed on Euronext Paris, some filings reference French regulatory requirements, including disclosures on shares outstanding and voting rights. These items help investors monitor the company’s capital structure and status as a French public company.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the key points of lengthy filings. Users can quickly identify the purpose of each Nanobiotix report, locate information on clinical programs, collaborations, and financing terms, and better understand how individual filings fit into the broader NBTX investment narrative.
Nanobiotix S.A. filed a Form 6-K to share a press release announcing its participation in several investor conferences in March. Company management, including CEO Laurent Levy and CFO & Business Officer Bart van Rhijn, will speak at healthcare and biotech events hosted by TD Cowen, UBS, Jefferies, and Leerink in Boston and Miami Beach. These appearances are intended to present the company’s late-stage nanotechnology-based oncology pipeline and broader platform to the investment community and other stakeholders.